Andersons pediatric cardiology 1674
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.6 KB, 3 trang )
cardiomyopathyduetoFabry'sdisease.NEnglJ
Med.1982;307(15):926–928.
174.NakaoS,TakenakaT,MaedaM,etal.An
atypicalvariantofFabry'sdiseaseinmenwith
leftventricularhypertrophy.NEnglJMed.
1995;333(5):288–293.
175.vonScheidtW,EngCM,FitzmauriceTF,etal.
AnatypicalvariantofFabry'sdiseasewith
manifestationsconfinedtothemyocardium.N
EnglJMed.1991;324(6):395–399.
176.WilsonHC,HopkinRJ,MaduemePC,etal.
Arrhythmiaandclinicalcardiacfindingsin
childrenwithAnderson-fabrydisease.AmJ
Cardiol.2017.
177.ShahJS,HughesDA,SachdevB,etal.
Prevalenceandclinicalsignificanceofcardiac
arrhythmiainAnderson-fabrydisease.AmJ
Cardiol.2005;96(6):842–846.
178.PatelV,O'MahonyC,HughesD,etal.Clinical
andgeneticpredictorsofmajorcardiaceventsin
patientswithAnderson-fabrydisease.Heart.
2015;101(12):961–966.
179.HopkinRJ,BisslerJ,BanikazemiM,etal.
Characterizationoffabrydiseasein352
pediatricpatientsinthefabryregistry.Pediatr
Res.2008;64(5):550–555.
180.MehtaA,ClarkeJT,GiuglianiR,etal.Natural
courseoffabrydisease:changingpatternof
causesofdeathinFOS-fabryoutcomesurvey.J
MedGenet.2009;46(8):548–552.
181.FrustaciA,ChimentiC,RicciR,etal.
Improvementincardiacfunctioninthecardiac
variantofFabry'sdiseasewithgalactoseinfusiontherapy.NEnglJMed.
2001;345(1):25–32.
182.TondelC,BostadL,LarsenKK,etal.
Agalsidasebenefitsrenalhistologyinyoung
patientswithfabrydisease.JAmSocNephrol.
2013;24(1):137–148.
183.ChimentiC,PieroniM,MorganteE,etal.
Prevalenceoffabrydiseaseinfemalepatients
withlate-onsethypertrophiccardiomyopathy.
Circulation.2004;110(9):1047–1053.
184.SachdevB,TakenakaT,TeraguchiH,etal.
PrevalenceofAnderson-fabrydiseaseinmale
patientswithlateonsethypertrophic
cardiomyopathy.Circulation.
2002;105(12):1407–1411.
185.EngelAG,GomezMR,SeyboldME,Lambert
EH.Thespectrumanddiagnosisofacidmaltase
deficiency.Neurology.1973;23(1):95–106.
186.vandenHoutHM,HopW,vanDiggelenOP,et
al.ThenaturalcourseofinfantilePompe's
disease:20originalcasescomparedwith133
casesfromtheliterature.Pediatrics.
2003;112(2):332–340.
187.KishnaniPS,HwuWL,MandelH,etal.A
retrospective,multinational,multicenterstudy
onthenaturalhistoryofinfantile-onsetpompe
disease.JPediatr.2006;148(5):671–676.
188.LaforetP,NicolinoM,EymardPB,etal.
Juvenileandadult-onsetacidmaltasedeficiency
inFrance:genotype-phenotypecorrelation.
Neurology.2000;55(8):1122–1128.
189.WinkelLP,HagemansML,vanDoornPA,etal.
Thenaturalcourseofnon-classicPompe's
disease;areviewof225publishedcases.J
Neurol.2005;252(8):875–884.
190.WokkeJH,AusemsMG,vandenBoogaardMJ,
etal.Genotype-phenotypecorrelationinadultonsetacidmaltasedeficiency.AnnNeurol.
1995;38(3):450–454.
191.KishnaniPS,CorzoD,NicolinoM,etal.
Recombinanthumanacid[alpha]-glucosidase:
majorclinicalbenefitsininfantile-onsetpompe
disease.Neurology.2007;68(2):99–109.
192.LevineJC,KishnaniPS,ChenYT,HerlongJR,
LiJS.Cardiacremodelingafterenzyme
replacementtherapywithacidalpha-glucosidase
forinfantswithpompedisease.PediatrCardiol.
2008;29(6):1033–1042.
